- Home
- GORO vs PBYI Comparison
GORO vs PBYI Comparison
Compare GORO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | PBYI |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.8M | 467.2M |
| IPO Year | 2011 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GORO | PBYI |
|---|---|---|
| Price | $3.38 | $9.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 307.6K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $1,049.78 | N/A |
| Revenue Next Year | $103.57 | $1.33 |
| P/E Ratio | ★ $70.67 | $131.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $4.58 |
| 52 Week High | $4.24 | $10.72 |
Technical Indicators
Market Signals| Indicator | GORO | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 51.63 |
| Support Level | $3.37 | $8.90 |
| Resistance Level | $4.00 | $10.04 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 62.77 | 38.13 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.